.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Understanding the Role of JAK Inhibitors

James Q. Del Rosso, DO, and Neal Bhatia, MD, discuss the role of topical and oral JAK inhibitors in inflammatory disease management.

EP. 1: JAK Inhibitors: An Overview

February 7th 2022

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

EP. 2: Topical JAK Inhibitors for Atopic Dermatitis

February 14th 2022

A review of topical JAK inhibitor ruxolitinib.

EP. 3: Oral JAK Inhibitors for Atopic Dermatitis

February 21st 2022

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

EP. 4: JAK Inhibitors: Non-Responders and Safety Considerations

February 28th 2022

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.